Cullinan Therapeutics, Inc.'s CLN-081 for Non Small Cell Lung Cancer: FDA decision expected February 27, 2027.
Key facts
PDUFA date2027-02-27
Business days away166
Drug / candidateCLN-081
IndicationNon Small Cell Lung Cancer
CompanyCullinan Therapeutics, Inc.
Market-cap tierSmall
Cohort decision-day move (history)±3% median
Cohort move is the historical median absolute decision-day move for this market-cap tier. History, not a prediction. See the full 2026 PDUFA calendar →
Not affiliated with or endorsed by the FDA. pdufa.bio is an independent publication with no affiliation with, endorsement by, sponsorship by, or connection to the U.S. Food and Drug Administration or any other government agency. “FDA”, “PDUFA” and all company, drug and ticker names are used descriptively and remain the property of their respective owners.
Informational and educational purposes only. Not investment advice. Nothing on this page is investment, legal, tax or medical advice, or an offer or solicitation to buy or sell any security. pdufa.bio is not a registered investment adviser or broker-dealer and does not recommend trades or publish individual-drug approval probabilities. Verify every date and outcome against primary FDA, SEC or company filings. Data is provided as is, without warranty of any kind, and past behaviour does not predict future outcomes.